Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs - PubMed (original) (raw)

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs

A M Krieg et al. Proc Natl Acad Sci U S A. 1998.

Abstract

Unmethylated CpG dinucleotides in particular base contexts (CpG-S motifs) are relatively common in bacterial DNA but are rare in vertebrate DNA. B cells and monocytes have the ability to detect such CpG-S motifs that trigger innate immune defenses with production of Th1-like cytokines. Despite comparable levels of unmethylated CpG dinucleotides, DNA from serotype 12 adenovirus is immune-stimulatory, but serotype 2 is nonstimulatory and can even inhibit activation by bacterial DNA. In type 12 genomes, the distribution of CpG-flanking bases is similar to that predicted by chance. However, in type 2 adenoviral DNA the immune stimulatory CpG-S motifs are outnumbered by a 15- to 30-fold excess of CpG dinucleotides in clusters of direct repeats or with a C on the 5' side or a G on the 3' side. Synthetic oligodeoxynucleotides containing these putative neutralizing (CpG-N) motifs block immune activation by CpG-S motifs in vitro and in vivo. Eliminating 52 of the 134 CpG-N motifs present in a DNA vaccine markedly enhanced its Th1-like function in vivo, which was increased further by the addition of CpG-S motifs. Thus, depending on the CpG motif, prokaryotic DNA can be either immune-stimulatory or neutralizing. These results have important implications for understanding microbial pathogenesis and molecular evolution and for the clinical development of DNA vaccines and gene therapy vectors.

PubMed Disclaimer

Figures

Figure 1

Induction of a Th2-like response by a CpG-N motif, and inhibition of the Th1-like response induced by a CpG-S motif. Anti-HBs antibody titers (IgG1 and IgG2a subclasses) in BALB/c mice 12 weeks after i.m. immunization with recombinant HBsAg, which was given alone (none) or with 10 μg stimulatory ODN (1826), 10 μg of neutralizing ODN (1631,

CGCGCGCGCGCGCGCGCGCG

; 1984, TCCATGC

TTCCTGC

TT; or 2010, G

CGCGCG

CCC; CpG dinucleotides are underlined for clarity) or with 10 μg stimulatory ODN + 10 μg neutralizing ODN. To improve nuclease resistance for these in vivo experiments, all ODN were phosphorothioate-modified. Each bar represents the group mean (n = 10 for none; n = 15 for 1826 and n = 5 for all other groups) for anti-HBs antibody titers as determined by end-point dilution ELISA assay. Solid portions of bars indicate antibodies of IgG1 subclass (Th2-like), and shaded portions indicate IgG2a subclass (Th1-like). The numbers above each bar indicate the IgG2a/IgG1 ratio in which a ratio >1 than indicates a predominantly Th1-like response and a ratio <1 indicates a predominantly Th2-like response (a value of 0 indicates a complete absence of IgG2a antibodies).

Figure 2

Enhancement of in vivo immune effects with optimized DNA vaccines. Mice were injected with 10 μg of pUK-S (solid bars), pMAS-S (open bars), pMCG16-S (lightly shaded bars), or pMCG50-S (darkly shaded bars) plasmid DNA bilaterally (50 μl at 0.1 mg/ml in saline) into the TA muscle as described (53). (A) The anti-HBs antibody response at 6 weeks (detected as described in Methods). Bars represent the group means (n = 5) for ELISA end-point dilution titers (performed in triplicate), and vertical lines represent the SEM. The numbers on the bars indicate the ratio of IgG2a/IgG1 antibodies at 4 weeks, as determined in separate assays (also in triplicate) by using pooled plasma. (B) CTL activity in specifically restimulated (5 days) splenocytes taken from mice 8 weeks after DNA immunization. Bars represent the group means (n = 3) for percentage of specific lysis (performed in triplicate) at an effector-to-target (E/T) ratio of 10:1; dots represent the individual values. Nonspecific lytic activity determined with non-antigen-presenting target cells, which never exceeds 10%, has been subtracted from values with HBsAg-expressing target cells to obtain percentage of specific lysis values.

References

1. Bird A P. Trends Genet. 1987;3:342–347.
1. Krieg A K, Yi A-K, Matson S, Waldschmidt T J, Bishop G A, Teasdale R, Koretzky G, Klinman D. Nature (London) 1995;374:546–549. - PubMed
1. Klinman D, Yi A-K, Beaucage S L, Conover J, Krieg A M. Proc Natl Acad Sci USA. 1996;93:2879–2883. - PMC - PubMed
1. Ballas Z K, Rasmussen W L, Krieg A M. J Immunol. 1996;157:1840–1845. - PubMed
1. Cowdery J S, Chace J H, Yi A-K, Krieg A M. J Immunol. 1996;156:4570–4575. - PubMed

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs - PubMed (original) (raw)